Results 201 to 210 of about 598,872 (375)

Adult NTRK-rearranged spindle cell neoplasms of the viscera: with an emphasis on rare locations and heterologous elements

Modern Pathology, 2022
Jen‐Wei Tsai, Jen-Chieh Lee, Tsung-Han Hsieh, Shih-Chiang Huang, Pei-Hang Lee, T. Liu, Yu-Chien Kao, Ching-Di Chang, T. Weng, Chien-Feng Li, Jung-Chia Lin, C. Liang, Yu-Li Su, I. Chang, Yu-Ting Wang, Nien-Yi Chang, Shih‐Chen Yu, Jui‐Chu Wang, Hsuan-Ying Huang   +18 more
semanticscholar   +1 more source

Human Papillomaviruses and Malignant Neoplasms of the Female Upper Reproductive Tract: A Comprehensive Review of the Literature. [PDF]

Cancers (Basel)
Karachalios C, Liapis I, Petousis S, Almperi EA, Margioula-Siarkou C, Margioula-Siarkou G, Flindris S, Karamitrousis E, Dinas K.   +8 more
europepmc   +1 more source

Uterine volume assay after gonadotoxic therapies in childhood, adolescence, and young adulthood: A systematic review and Bayesian network meta‐analysis

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
Recent studies have suggested the potential impact of high doses of chemotherapy on uterine volume, but this meta‐analysis did not find any significant decrease in uterine volume after chemotherapy. Abstract Introduction Uterine damage after pelvic radiotherapy or total‐body irradiation is well described, with decreased uterine volume and high ...
Eloïse Fraison, Stephanie Huberlant, Mathilde Cavalieri, Aurore Gueniffey, Justine Riss, Christine Rousset‐Jablonski, Blandine Courbiere   +6 more
wiley   +1 more source

A large pedunculated subserosal myoma with cystic and red degeneration: A case report with literature review. [PDF]

Radiol Case Rep
Oukassem S, Abourak C, Guennouni A, Belkouchi L, Allali N, Chat L, El Haddad S, Laaboud K, Bennaceur S, Douraidi N, Rachid M, El Hanchi Z.   +11 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Concurrence of abdominal wall desmoid tumor with uterine sub-serosal fibroid: A rare case report from Nepal. [PDF]

Int J Surg Case Rep
Yadav KK, Pokhrel M, Dhenga S, Sah G, Bhandari G, Adhikari P.   +5 more
europepmc   +1 more source

THE QUESTION OF THE ORIGIN OF MALIGNANT FROM NON-MALIGNANT UTERINE NEOPLASMS

, 1896
W. Roger Williams
openalex   +2 more sources

GPCR‐G protein signalling and its mutational landscape in cancer—Driver or passenger

British Journal of Pharmacology, EarlyView.
G protein‐coupled receptors (GPCRs) play a crucial role in cellular signalling, regulating various physiological processes. Abnormal expression and mutations of GPCRs have been implicated in several types of cancer, influencing tumour initiation, progression and immune response.
Chenlin Feng, Jasper F. Ooms, Erik H. J. Danen, Laura H. Heitman   +3 more
wiley   +1 more source

Clinicopathological pitfalls associated with benign uterine mesenchymal tumors: A single-center experience. [PDF]

Medicine (Baltimore)
Iwabuchi S, Sato Y, Okamoto M, Yano M, Kobayashi E.   +4 more
europepmc   +1 more source

The Time Lag Associated With the Reclassification of Germline BRCA Variants' Pathogenicity Is Critical for Cancer Patients

Cancer Science, EarlyView.
The period for reclassifying the variants' pathogenicity is too long for patients with advanced or recurrent cancers with variants of uncertain significance that can be objectively re‐evaluated to be (likely) pathogenic according to accumulated evidence.
Tomomi Hayashi, Hiroyuki Matsubayashi, Yoshimi Kiyozumi   +2 more
wiley   +1 more source